Holen Sie sich die Stockscreener-App
5.38
15.67%
-1.00
Handel nachbörslich:
5.71
0.33
+6.13%
Tevogen Bio Holdings Inc Aktie (TVGN) Neueste Nachrichten
Tevogen reports performance advancements for Tevogen.AI platform - TipRanks
Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization - The Globe and Mail
Tevogen Bio Advances AI Drug Development Platform with Improved Predictive Accuracy for Target Identification - Quiver Quantitative
Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics ... - Caledonian Record
Inside the AI model Tevogen is training to cut trial-and-error in drug R&D - Stock Titan
Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform - Finviz
Wall Street Recap: Is Tevogen Bio Holdings Inc Equity Warrant undervalued by DCF analysisEarnings Overview Report & Real-Time Market Trend Scan - baoquankhu1.vn
Tevogen Bio Holdings Inc. is considering the acquisition of Sciometrix and Clinicus platforms to enhance its monitoring capabilities for Long Covid. - Bitget
Tevogen Bio Accelerates Development of TVGN 489 for Long COVID with New Leadership and Strategic Initiatives - Quiver Quantitative
Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform - GlobeNewswire Inc.
Tevogen appoints interim leaders across core business verticals - TipRanks
Tevogen Bio Holdings Inc. Appoints Interim Leaders to Drive Diversified Growth Strategy - Quiver Quantitative
Inside Tevogen's $50M expansion push and the team picked to run it - Stock Titan
Total debt of Tevogen Bio Holdings Inc. – FWB:G280 - TradingView
Total operating expenses of Tevogen Bio Holdings Inc. – FWB:G280 - TradingView
Operating income of Tevogen Bio Holdings Inc. – TRADEGATE:G280 - TradingView
Tevogen Bio Holdings Inc. Income Statement – FWB:G280 - TradingView
Market Review: Is Tevogen Bio Holdings Inc Equity Warrant undervalued by DCF analysis - baoquankhu1.vn
Portfolio Shifts: Why is Tevogen Bio Holdings Inc Equity Warrant stock going upWeekly Trade Review & Expert Verified Movement Alerts - baoquankhu1.vn
Letter to Shareholders from CEO Dr. Ryan Saadi - The Globe and Mail
Tevogen CEO says ‘actively evaluating potential acquisitions’ - TipRanks
Tevogen Bio explores acquisitions that may add $50M+ in yearly revenue - Stock Titan
Tevogen Bio Explores Buyout To Boost Generics Platform - Benzinga
Tevogen Bio (NASDAQ:TVGN) Sets New 12-Month LowHere's What Happened - MarketBeat
Marvell Technology, Day One Biopharmaceuticals, Samsara And Other Big Stocks Moving Higher On Friday - Benzinga
Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical - Sahm
Tevogen Bio Signs Letter of Intent to Evaluate Potential Apozeal Pharmaceutical Acquisition - marketscreener.com
U.S. federal banking regulators clarify capital treatment rules for tokenized securities - Bitget
Tevogen Bio Holdings (Tevogen) has recently taken a key step in its generic drug business strategy, signing a letter of intent to officially begin evaluating the potential acquisition of Apozeal Pharmaceuticals. - Bitget
Tevogen Bio Holdings Inc is currently actively evaluating other transaction opportunities and has strategically focused its priorities on businesses related to the life sciences sector. - Bitget
Tevogen Bio Holdings Inc. Signs Letter of Intent to Explore Acquisition of Apozeal Pharmaceutical Inc. for Generics Expansion - Quiver Quantitative
Tevogen Announces Reverse Stock Split - Bitget
TVGN Downgrade: Analyst Shifts Rating from Buy to Hold | TVGN St - GuruFocus
Tevogen Shares Plunge 22% After Reverse Stock Split Announcement - Nasdaq
Tevogen Bio Announces 1-for-50 Reverse Stock Split - TipRanks
1-for-50 Reverse Split Effective Mar 6, 2026 — Tevogen (NASDAQ: TVGN) - Stock Titan
Tevogen Bio (Nasdaq: TVGN) sets 1-for-50 reverse stock split to meet Nasdaq bid rule - Stock Titan
Tevogen announces reverse stock split - marketscreener.com
Tevogen to swap every 50 shares for 1 in bid to meet Nasdaq rules - Stock Titan
TVGN: Analyst Lowers Price Target by 60% While Maintaining Buy R - GuruFocus
D. Boral Capital lowers Tevogen Bio stock price target to $2 on dilution risk By Investing.com - Investing.com South Africa
D. Boral Capital lowers Tevogen Bio stock price target to $2 on dilution risk - Investing.com
Tevogen Bio Signs Letter of Intent to Explore Contract Research Organization Acquisition - marketscreener.com
Tevogen Bio Holdings Inc. Signs Non-Binding Letter of Intent to Explore Potential Transaction with Global Contract Research Organization - Quiver Quantitative
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization - Taiwan News
Tevogen weighs CRO acquisition to add service revenue, optimize trials - Stock Titan
UPDATETevogen Signs Letter of Intent to Evaluate - GlobeNewswire
Tevogen signs loi to evaluate potential acquisition of Sciometrix - marketscreener.com
Tevogen (NASDAQ: TVGN) approves reverse split and 100M plan increase - Stock Titan
Tevogen Bio Holdings Inc. Signs Letter of Intent to Explore Acquisition of Sciometrix Inc. for Enhanced Healthcare Solutions | TVGN Stock News - Quiver Quantitative
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus - Taiwan News
Tevogen Bio Shareholders Approve Reverse Split Authorization - TipRanks
Ryan Saadi: Innovative Biotech Leader, Tevogen Bio Founder and CEO, and Champion of Accessible Immunotherapy - BBN Times
TVGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Inflation Data: Is NESR stock a buy or sell2025 Investor Takeaways & Growth Focused Entry Reports - baoquankhu1.vn
Is Psyence Biomedical Ltds ROIC above industry averageJuly 2025 News Drivers & Fast Entry High Yield Stock Tips - baoquankhu1.vn
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):